ID   SK-MEL-192
AC   CVCL_6101
SY   SK-Mel-192; SKMEL-192; SKMEL192
DR   cancercelllines; CVCL_6101
DR   Cosmic; 685211
DR   Cosmic; 1122262
DR   Cosmic; 1669189
DR   GEO; GSM555131
DR   GEO; GSM555184
DR   Lonza; 1341
DR   Progenetix; CVCL_6101
DR   Wikidata; Q54953899
RX   PubMed=18505964;
RX   PubMed=21343389;
RX   PubMed=21725359;
RX   PubMed=24576830;
CC   From: Memorial Sloan Kettering Cancer Center; New York; USA.
CC   Sequence variation: Mutation; HGNC; HGNC:1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=21725359; PubMed=24576830).
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Derived from site: Metastatic; Not specified.
DI   NCIt; C3224; Melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 19-12-24; Version: 22
//
RX   PubMed=18505964; DOI=10.1093/jnci/djn157; PMCID=PMC4410798;
RA   Freedberg D.E., Rigas S.H., Russak J.E., Gai W.-M., Kaplow M.E.,
RA   Osman I., Turner F., Randerson-Moor J.A., Houghton A.N., Busam K.J.,
RA   Bishop D.T., Bastian B.C., Newton-Bishop J.A., Polsky D.;
RT   "Frequent p16-independent inactivation of p14ARF in human melanoma.";
RL   J. Natl. Cancer Inst. 100:784-795(2008).
//
RX   PubMed=21343389; DOI=10.1158/0008-5472.CAN-10-2958; PMCID=PMC3070783;
RA   Rose A.E., Poliseno L., Wang J.-H., Clark M., Pearlman A., Wang G.-M.,
RA   Vega y Saenz de Miera E.C., Medicherla R., Christos P.J., Shapiro R.,
RA   Pavlick A., Darvishian F., Zavadil J., Polsky D., Hernando E.,
RA   Ostrer H., Osman I.;
RT   "Integrative genomics identifies molecular alterations that challenge
RT   the linear model of melanoma progression.";
RL   Cancer Res. 71:2561-2571(2011).
//
RX   PubMed=21725359; DOI=10.1038/onc.2011.250; PMCID=PMC3267014;
RA   Xing F., Persaud Y., Pratilas C.A., Taylor B.S., Janakiraman M.,
RA   She Q.-B., Gallardo H.F., Liu C., Merghoub T., Hefter B.E., Dolgalev I.,
RA   Viale A.J., Heguy A., de Stanchina E., Cobrinik D., Bollag G.,
RA   Wolchok J.D., Houghton A.N., Solit D.B.;
RT   "Concurrent loss of the PTEN and RB1 tumor suppressors attenuates RAF
RT   dependence in melanomas harboring (V600E)BRAF.";
RL   Oncogene 31:446-457(2012).
//
RX   PubMed=24576830; DOI=10.1158/0008-5472.CAN-13-2625; PMCID=PMC4005042;
RA   Nissan M.H., Pratilas C.A., Jones A.M., Ramirez R., Won H., Liu C.-L.,
RA   Tiwari S., Kong L., Hanrahan A.J., Yao Z., Merghoub T., Ribas A.,
RA   Chapman P.B., Yaeger R.D., Taylor B.S., Schultz N., Berger M.F.,
RA   Rosen N., Solit D.B.;
RT   "Loss of NF1 in cutaneous melanoma is associated with RAS activation
RT   and MEK dependence.";
RL   Cancer Res. 74:2340-2350(2014).
//